Autolus Therapeutics Plc ADR (AUTL)

$1.57 -0.04 (-2.48%)
Market Cap 428.49M
Revenue (ttm) 75.39M
Net Income (ttm) -287.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -381.39%
Debt to Equity Ratio 0.00
Volume 1,204,300
Avg Vol 1,563,898
Day's Range N/A - N/A
Shares Out 266.14M
Stochastic %K 50%
Beta 1.93
Analysts Strong Sell
Price Target $8.79

Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 3829 6230
Address:
The Mediaworks, 191 Wood Lane White City, London, United Kingdom
gandolf63
gandolf63 May. 8 at 10:53 PM
$AUTL its not a slam dunk yet for in vivo. This is a good article that explains the challanges https://pmc.ncbi.nlm.nih.gov/articles/PMC13096480/ “Thus, in vivo-generated CAR cells confront a dual challenge: they lack the exogenous cytokine and co-stimulatory support available in vitro, while simultaneously facing inhibitory pressures from the pathological microenvironment—be it tumor-related or autoimmunity-driven. Together, these factors lead to limited expansion, reduced survival, insufficient memory subset formation, and impaired resistance to exhaustion, ultimately compromising therapeutic durability and efficacy “
0 · Reply
gandolf63
gandolf63 May. 8 at 5:38 PM
$AUTL seems like scam street has ignored their entire pipeline in determining share price
1 · Reply
Michael_garic
Michael_garic May. 8 at 3:21 PM
$AUTL Tecartus is used for both Mantle Cell and B ALL indications. Estimated B ALL is 20% - 40% of total sales. AUTL only competes in B ALL, while majority of Tecartus is for MCL. This would indicate to me that AUTL is probably getting most of the B ALL business.
0 · Reply
MorganHoratio
MorganHoratio May. 8 at 1:24 PM
Google just released its updated 13F filing which shows all the stocks it owned as of the end of Q1: $ARM - 1,960,784 shares $ASTS - 8,943,486 $AUTL - 698,262 $BEAM - 321,604 $BBIO - 2,823,126 Google's Q1 13F is a masterclass in Space, Silicon, and AI Bio! The standout is definitely the 8.9M share stake in $ASTS. Despite the looming SpaceX IPO, Google is doubling down on this "Space-based Cell Tower"—a clear play for global Gemini AI dominance. $ARM remains the bedrock of its custom silicon (Axion) strategy, while $BEAM and $BBIO highlight a massive pivot into AI-driven drug discovery. Do you think $ASTS is Google's ultimate strategic hedge against Starlink in 2026? Which of these deep-tech plays are you adding to your watchlist?
0 · Reply
Joe_90_
Joe_90_ May. 8 at 1:01 PM
$AUTL folks all you have to do is research Ryan Richardsons package on joining Autolus, this man is visionary, just do your DD see the package, you'll soon see the plan, otherwise might be best if you sold your shares and go elsewhere, bears you will be called out to defend position, so think before you post
1 · Reply
Michael_garic
Michael_garic May. 8 at 12:03 PM
$AUTL Large block bought, 14500 shares, in premarket this morning at 1.70.
1 · Reply
resume777
resume777 May. 8 at 10:05 AM
$AUTL
0 · Reply
Michael_garic
Michael_garic May. 7 at 11:03 PM
$AUTL dgbio read the whole thing...
0 · Reply
Michael_garic
Michael_garic May. 7 at 11:02 PM
$AUTL
0 · Reply
Michael_garic
Michael_garic May. 7 at 11:01 PM
$AUTL
0 · Reply
Latest News on AUTL
Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026

May 5, 2026, 7:00 AM EDT - 3 days ago

Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026

Autolus Therapeutics to reduce workforce by approximately 13%

2026-04-29T22:04:39.000Z - 9 days ago

Autolus Therapeutics to reduce workforce by approximately 13%

Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction

Apr 29, 2026, 4:05 PM EDT - 9 days ago

Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 21, 2026, 4:10 PM EDT - 17 days ago

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Autolus Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 13, 2026, 10:15 AM EDT - 25 days ago

Autolus Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Autolus Therapeutics files to sell 54.58M American Depositary Shares for holders

2026-04-13T10:06:36.000Z - 25 days ago

Autolus Therapeutics files to sell 54.58M American Depositary Shares for holders

Autolus Therapeutics files $150M mixed securities shelf

2026-04-13T10:06:09.000Z - 25 days ago

Autolus Therapeutics files $150M mixed securities shelf

Autolus Therapeutics Transcript: Status update

Apr 8, 2026, 1:00 PM EDT - 4 weeks ago

Autolus Therapeutics Transcript: Status update

Autolus Therapeutics to Participate in Upcoming Investor Conferences

Apr 7, 2026, 7:00 AM EDT - 4 weeks ago

Autolus Therapeutics to Participate in Upcoming Investor Conferences

Autolus Therapeutics price target lowered to $10 from $12 at Mizuho

2026-03-31T11:07:21.000Z - 5 weeks ago

Autolus Therapeutics price target lowered to $10 from $12 at Mizuho

Autolus Therapeutics Earnings Call Transcript: Q4 2025

Mar 27, 2026, 8:30 AM EDT - 6 weeks ago

Autolus Therapeutics Earnings Call Transcript: Q4 2025

Autolus Therapeutics reports Q4 EPS (34c), consensus (43c)

2026-03-27T11:36:34.000Z - 6 weeks ago

Autolus Therapeutics reports Q4 EPS (34c), consensus (43c)

Options Volatility and Implied Earnings Moves Today, March 27, 2026

2026-03-27T11:05:12.000Z - 6 weeks ago

Options Volatility and Implied Earnings Moves Today, March 27, 2026

CCL HUMA KOPN LGN TMC

Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Mar 27, 2026, 7:00 AM EDT - 6 weeks ago

Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026

Mar 16, 2026, 4:10 PM EDT - 7 weeks ago

Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026

Autolus Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 11:10 AM EST - 2 months ago

Autolus Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Autolus Therapeutics initiated with a Buy at H.C. Wainwright

2026-02-17T11:11:16.000Z - 2 months ago

Autolus Therapeutics initiated with a Buy at H.C. Wainwright

Autolus Therapeutics price target lowered to $8 from $11 at H.C. Wainwright

2026-02-13T11:43:09.000Z - 3 months ago

Autolus Therapeutics price target lowered to $8 from $11 at H.C. Wainwright

Autolus Therapeutics reports inducement grants under Nasdaq listing rule

2026-02-04T14:01:01.000Z - 3 months ago

Autolus Therapeutics reports inducement grants under Nasdaq listing rule

Autolus Therapeutics price target lowered to $8 from $10 at Truist

2026-01-13T14:02:20.000Z - 4 months ago

Autolus Therapeutics price target lowered to $8 from $10 at Truist

Autolus Therapeutics price target lowered to $10 from $11 at Needham

2026-01-12T16:55:27.000Z - 4 months ago

Autolus Therapeutics price target lowered to $10 from $11 at Needham

Autolus Therapeutics sees Q4 AUCATZYL revenue of $24M

2026-01-12T12:11:24.000Z - 4 months ago

Autolus Therapeutics sees Q4 AUCATZYL revenue of $24M

Autolus Therapeutics sees FY26 AUCATZYL revenue $120M-$135M

2026-01-12T12:11:07.000Z - 4 months ago

Autolus Therapeutics sees FY26 AUCATZYL revenue $120M-$135M

Autolus Therapeutics sees cash runway into 4Q27

2026-01-12T12:10:09.000Z - 4 months ago

Autolus Therapeutics sees cash runway into 4Q27

Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026

Jan 12, 2026, 7:00 AM EST - 4 months ago

Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026

Autolus Therapeutics to evaluate automated manufacturing of AUCATZYL

2026-01-06T14:15:14.000Z - 4 months ago

Autolus Therapeutics to evaluate automated manufacturing of AUCATZYL

Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform

Jan 6, 2026, 9:00 AM EST - 4 months ago

Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform

Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform

Jan 6, 2026, 9:00 AM EST - 4 months ago

Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform

Needham ups Autolus target, names top pick for 2026

2025-12-29T13:05:39.000Z - 4 months ago

Needham ups Autolus target, names top pick for 2026

Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025

Dec 8, 2025, 4:05 PM EST - 5 months ago

Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025

Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025

Dec 8, 2025, 8:35 AM EST - 5 months ago

Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025

Autolus Therapeutics Appoints Ryan Richardson to Board of Directors

Dec 1, 2025, 7:00 AM EST - 5 months ago

Autolus Therapeutics Appoints Ryan Richardson to Board of Directors

NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹

Nov 25, 2025, 4:00 AM EST - 5 months ago

NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹

Autolus Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 7:30 AM EST - 6 months ago

Autolus Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Nov 13, 2025, 4:05 PM EST - 6 months ago

Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Autolus Therapeutics Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:30 AM EST - 6 months ago

Autolus Therapeutics Earnings Call Transcript: Q3 2025

Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Nov 12, 2025, 7:00 AM EST - 6 months ago

Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025

Nov 3, 2025, 9:05 AM EST - 6 months ago

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025

Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

Oct 30, 2025, 7:00 AM EDT - 6 months ago

Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025

Oct 27, 2025, 7:00 AM EDT - 6 months ago

Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025

Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis

Oct 20, 2025, 7:00 AM EDT - 7 months ago

Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis

Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025

Sep 16, 2025, 8:05 AM EDT - 8 months ago

Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025

Autolus Therapeutics Earnings Call Transcript: Q2 2025

Aug 12, 2025, 8:30 AM EDT - 9 months ago

Autolus Therapeutics Earnings Call Transcript: Q2 2025

Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Aug 12, 2025, 7:00 AM EDT - 9 months ago

Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

Jul 24, 2025, 7:30 AM EDT - 10 months ago

Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

Autolus Therapeutics' CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Jul 21, 2025, 7:00 AM EDT - 10 months ago

Autolus Therapeutics' CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

Jun 12, 2025, 2:00 AM EDT - 11 months ago

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

Autolus Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 11, 2025, 1:20 PM EDT - 11 months ago

Autolus Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Autolus Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 3:10 PM EDT - 1 year ago

Autolus Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

May 23, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress

May 14, 2025, 9:30 AM EDT - 1 year ago

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress

Autolus Therapeutics Earnings Call Transcript: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Earnings Call Transcript: Q1 2025

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

May 8, 2025, 7:00 AM EDT - 1 year ago

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

Apr 25, 2025, 12:06 PM EDT - 1 year ago

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

Autolus Therapeutics Transcript: Status Update

Apr 23, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Transcript: Status Update

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Apr 22, 2025, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Autolus Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 9, 2025, 9:30 AM EDT - 1 year ago

Autolus Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

Autolus Therapeutics Earnings Call Transcript: Q4 2024

Mar 20, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Earnings Call Transcript: Q4 2024

Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 20, 2025, 7:00 AM EDT - 1 year ago

Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Autolus Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 12, 2025, 8:40 AM EDT - 1 year ago

Autolus Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

Mar 6, 2025, 7:00 AM EST - 1 year ago

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

Jan 17, 2025, 7:00 AM EST - 1 year ago

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Dec 9, 2024, 7:30 PM EST - 1 year ago

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Autolus Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 21, 2024, 8:00 AM EST - 1 year ago

Autolus Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Autolus Therapeutics Earnings Call Transcript: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Autolus Therapeutics Earnings Call Transcript: Q3 2024

Autolus Therapeutics Transcript: FDA Announcement

Nov 11, 2024, 8:30 AM EST - 1 year ago

Autolus Therapeutics Transcript: FDA Announcement

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Nov 8, 2024, 4:23 PM EST - 1 year ago

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Oct 28, 2024, 5:00 PM EDT - 1 year ago

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Autolus Therapeutics Earnings Call Transcript: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Earnings Call Transcript: Q2 2024

Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

Jul 26, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

Jun 14, 2024, 7:00 AM EDT - 2 years ago

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

Autolus Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 12, 2024, 2:40 PM EDT - 2 years ago

Autolus Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Autolus Therapeutics Transcript: Jefferies Global Healthcare Conference

Jun 6, 2024, 7:30 AM EDT - 2 years ago

Autolus Therapeutics Transcript: Jefferies Global Healthcare Conference

Autolus Therapeutics Transcript: Status Update

Jun 1, 2024, 9:30 AM EDT - 2 years ago

Autolus Therapeutics Transcript: Status Update

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO

May 31, 2024, 8:00 AM EDT - 2 years ago

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO

Autolus Therapeutics Earnings Call Transcript: Q1 2024

May 17, 2024, 8:30 AM EDT - 2 years ago

Autolus Therapeutics Earnings Call Transcript: Q1 2024

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

May 17, 2024, 7:00 AM EDT - 2 years ago

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

Apr 24, 2024, 10:00 AM EDT - 2 years ago

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Apr 23, 2024, 7:00 AM EDT - 2 years ago

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Autolus Therapeutics Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 11, 2024, 9:30 AM EDT - 2 years ago

Autolus Therapeutics Transcript: 23rd Annual Needham Virtual Healthcare Conference

Autolus Therapeutics Announces Changes to its Board of Directors

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Autolus Therapeutics Announces Changes to its Board of Directors

Autolus Therapeutics Earnings Call Transcript: Q4 2023

Mar 14, 2024, 9:00 AM EDT - 2 years ago

Autolus Therapeutics Earnings Call Transcript: Q4 2023

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

Mar 14, 2024, 7:00 AM EDT - 2 years ago

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

Mar 12, 2024, 7:00 AM EDT - 2 years ago

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024

Feb 29, 2024, 7:00 AM EST - 2 years ago

Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024

Autolus Announces Pricing of Underwritten Offering

Feb 8, 2024, 7:00 AM EST - 2 years ago

Autolus Announces Pricing of Underwritten Offering

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

Feb 8, 2024, 5:45 AM EST - 2 years ago

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

gandolf63
gandolf63 May. 8 at 10:53 PM
$AUTL its not a slam dunk yet for in vivo. This is a good article that explains the challanges https://pmc.ncbi.nlm.nih.gov/articles/PMC13096480/ “Thus, in vivo-generated CAR cells confront a dual challenge: they lack the exogenous cytokine and co-stimulatory support available in vitro, while simultaneously facing inhibitory pressures from the pathological microenvironment—be it tumor-related or autoimmunity-driven. Together, these factors lead to limited expansion, reduced survival, insufficient memory subset formation, and impaired resistance to exhaustion, ultimately compromising therapeutic durability and efficacy “
0 · Reply
gandolf63
gandolf63 May. 8 at 5:38 PM
$AUTL seems like scam street has ignored their entire pipeline in determining share price
1 · Reply
Michael_garic
Michael_garic May. 8 at 3:21 PM
$AUTL Tecartus is used for both Mantle Cell and B ALL indications. Estimated B ALL is 20% - 40% of total sales. AUTL only competes in B ALL, while majority of Tecartus is for MCL. This would indicate to me that AUTL is probably getting most of the B ALL business.
0 · Reply
MorganHoratio
MorganHoratio May. 8 at 1:24 PM
Google just released its updated 13F filing which shows all the stocks it owned as of the end of Q1: $ARM - 1,960,784 shares $ASTS - 8,943,486 $AUTL - 698,262 $BEAM - 321,604 $BBIO - 2,823,126 Google's Q1 13F is a masterclass in Space, Silicon, and AI Bio! The standout is definitely the 8.9M share stake in $ASTS. Despite the looming SpaceX IPO, Google is doubling down on this "Space-based Cell Tower"—a clear play for global Gemini AI dominance. $ARM remains the bedrock of its custom silicon (Axion) strategy, while $BEAM and $BBIO highlight a massive pivot into AI-driven drug discovery. Do you think $ASTS is Google's ultimate strategic hedge against Starlink in 2026? Which of these deep-tech plays are you adding to your watchlist?
0 · Reply
Joe_90_
Joe_90_ May. 8 at 1:01 PM
$AUTL folks all you have to do is research Ryan Richardsons package on joining Autolus, this man is visionary, just do your DD see the package, you'll soon see the plan, otherwise might be best if you sold your shares and go elsewhere, bears you will be called out to defend position, so think before you post
1 · Reply
Michael_garic
Michael_garic May. 8 at 12:03 PM
$AUTL Large block bought, 14500 shares, in premarket this morning at 1.70.
1 · Reply
resume777
resume777 May. 8 at 10:05 AM
$AUTL
0 · Reply
Michael_garic
Michael_garic May. 7 at 11:03 PM
$AUTL dgbio read the whole thing...
0 · Reply
Michael_garic
Michael_garic May. 7 at 11:02 PM
$AUTL
0 · Reply
Michael_garic
Michael_garic May. 7 at 11:01 PM
$AUTL
0 · Reply
Michael_garic
Michael_garic May. 7 at 8:54 PM
$AUTL I listened to the Oncology portion of the Gilead call. They showed a chart that showed Tecartus WW sales at 75M in Q1 2026, down from 78M in Q1 2025 (4%) and from 90M in Q4 2025 (17%). They didn't break out US sales, maybe that will come out in the detailed press release. The US data will tell us the real story.
1 · Reply
Joe_90_
Joe_90_ May. 7 at 8:52 PM
$AUTL i think its time, let's walk up the stairs ;)
1 · Reply
Joe_90_
Joe_90_ May. 7 at 8:41 PM
$AUTL Tecartus down to $75M from $90M Q1 26 -12% YOY, and -11% QOQ by competitive headwinds
0 · Reply
Biotechs5454
Biotechs5454 May. 7 at 8:21 PM
$AUTL Tecartus $75MM down 5% primarily due to “in class competition”
0 · Reply
dgbio
dgbio May. 7 at 8:20 PM
$AUTL Tecartus US sales are 30m in Q1'26. Drop of 25% YoY and a new low.
2 · Reply
Michael_garic
Michael_garic May. 7 at 8:17 PM
$AUTL For Gilead Tecartus....sorry last post was for Q4... still waiting on Q1 details
0 · Reply
Michael_garic
Michael_garic May. 7 at 8:07 PM
$AUTL Tecartus Performance (brexucabtagene autoleucel, a CAR-T cell therapy for certain lymphomas/leukemias) Q4 2025: Sales of $90 million, down 9% year-over-year (YoY), primarily due to in-class competition. Full Year 2025: Sales of $344 million, down 15% YoY, again driven mainly by competitive pressures in the cell therapy space. This continues a trend of declines seen in prior quarters of 2025 (e.g., down 22% in Q1, 14% in Q2, 15% in Q3), reflecting ongoing headwinds for Gilead's cell therapy portfolio (Yescarta + Tecartus).
1 · Reply
TricksterT
TricksterT May. 7 at 6:39 PM
Gilead Sciences Set to Release Q1 Earnings on May 7 | Intellectia.AI $AUTL reporting after hours and might be telling on how Autolus ER is going to go. https://intellectia.ai/news/stock/gilead-sciences-set-to-release-q1-earnings-on-may-7
0 · Reply
TricksterT
TricksterT May. 7 at 4:10 PM
$AUTL $1.20 I wouldn’t jump in above that. Nice swings from this range to $1.60.
1 · Reply
dfung02
dfung02 May. 7 at 3:08 PM
$AUTL Added 3000 shares more at $1.61.
0 · Reply
Roadto1mio
Roadto1mio May. 7 at 2:00 PM
$AUTL let her breath, she made 70% in a few weeks
0 · Reply
Flying_Trader2
Flying_Trader2 May. 7 at 1:42 PM
$AUTL This is no longer a “science project” stock. The market is going to care about : > Launch execution > Manufacturing throughput > Margin improvement > Evidence of scaling And this quarter better inspire confidence or $1.20 we shall see again.
1 · Reply